Home Data Calendar Blog

RCUS

Tables

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Common Stock Value 0.010.010.010.010.010.010.010.010.010.010.000.000.000.000.000.00NANANANANA
Weighted Average Number Of Diluted Shares Outstanding 72.24NANANA70.11NANA63.5365.1548.5644.28NA43.94NANANANANANANANA
Weighted Average Number Of Shares Outstanding Basic 72.24NANANA70.11NANA63.5362.6050.1545.95NA45.7945.4144.53NA44.4544.4511.60NA3.99
Weighted Average Number Of Share Outstanding Basic And Diluted NA71.8171.19NANA69.7567.08NANA48.5644.2844.0643.9443.8043.5143.1642.8442.539.492.211.95
Earnings Per Share Basic -0.90NANA4.04-1.11NANA-0.870.03NANA-0.37-0.51NANANANANANANANA
Earnings Per Share Diluted -0.90NANA3.99-1.11NANA-0.870.03NANA-0.37-0.51NANANANANANANANA
Earnings Per Share Basic And Diluted NA-0.93-0.96NANA-1.09-1.08NANA-0.93-0.63-0.37-0.51-0.64-0.41-0.27-0.25-0.32-1.37-5.56-11.86
Income Loss From Continuing Operations Per Basic Share -0.00NANA0.00-0.00NANA-0.000.00-0.00-0.00-0.00-0.00NANANANANANANANA
Income Loss From Continuing Operations Per Diluted Share -0.00NANA0.00-0.00NANA-0.000.00-0.00-0.00-0.00-0.00NANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Revenue From Contract With Customer Excluding Assessed Tax 33.5826.7618.00354.509.469.469.469.4964.531.751.759.751.751.751.751.564.291.251.251.250.16
Revenues 33.5826.7618.00354.509.469.469.469.4964.531.751.759.751.751.751.751.564.291.251.251.250.16
Operating Expenses 102.9895.7485.1973.2387.6085.6082.2161.5062.9847.1230.1527.2825.0030.9120.5215.0516.4417.1514.5814.5923.30
Research And Development Expense 76.6869.9161.2149.9471.2568.7766.3948.7151.8035.6923.1420.6917.2425.0015.5511.4412.8613.7011.6512.1521.43
General And Administrative Expense 26.2925.8423.9723.3016.3416.8315.8212.7911.1811.437.016.597.765.914.973.613.583.452.932.451.86
Operating Income Loss -69.40-68.98-67.18281.27-78.14-76.14-72.75-52.011.55-45.38-28.40-17.53-23.25-29.16-18.77-13.48-12.14-15.90-13.33-13.34-23.13
Allocated Share Based Compensation Expense 16.2615.6816.54NA14.5913.3712.76NA6.004.473.46NA2.742.131.67NA1.051.120.66NA0.14
Income Tax Expense Benefit 0.000.001.00NANANANANANANANANANANANANANANANANANA
Income Taxes Paid 0.00NANANANANANANANANANANANANANANANANANANANA
Profit Loss -64.92-66.63-67.99279.37-77.97-75.97-72.59-51.851.82-45.07-27.75-16.60-22.35-28.09-17.67-12.29-10.81-13.53-12.95-13.21NA
Other Comprehensive Income Loss Net Of Tax -2.56-2.58-3.40NA-0.05-0.04-0.05NA-0.06-0.140.22NA-0.060.080.14NA-0.030.01-0.06NANA
Net Income Loss -64.92-66.63-67.99279.37-77.97-75.97-72.59-51.851.82-45.07-27.75-16.60-22.35-28.09-17.67-12.29-10.81-13.53-12.95-13.21-23.12
Comprehensive Income Net Of Tax -67.48-69.22-71.39278.20-78.02-76.01-72.64-51.891.76-45.22-27.53-16.59-22.41-28.01-17.53-12.29-10.84-13.52-13.01-13.24-23.11

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Assets 1393.821476.771543.431591.90839.29898.77935.12772.29811.08481.39176.14203.11216.96238.97258.53274.93286.72293.87305.40190.49NA
Liabilities 695.12729.39746.85750.45296.68294.22270.33269.99266.6652.6835.5139.2739.7342.3336.9639.9841.6039.2938.8136.62NA
Liabilities And Stockholders Equity 1393.821476.771543.431591.90839.29898.77935.12772.29811.08481.39176.14203.11216.96238.97258.53274.93286.72293.87305.40190.49NA
Stockholders Equity 698.70747.39796.58841.45542.61604.55664.79502.30544.42428.71140.64163.84177.23196.65221.57234.94245.12254.57266.59-72.33NA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Assets Current 1101.121227.471264.231261.75545.29745.95841.87735.82797.20471.60166.22192.71200.49227.73245.01258.95265.28267.44282.07176.87NA
Cash And Cash Equivalents At Carrying Value 217.65272.63548.78147.91179.43320.48390.26173.41221.85285.1967.3357.9478.9976.0768.5071.0674.89170.00198.1298.4318.31
Prepaid Expense And Other Assets Current 21.6215.6718.5315.6217.5721.978.685.4711.828.668.014.304.223.273.082.322.331.551.831.14NA
Available For Sale Securities Debt Securities 1191.921271.111342.37681.30NANANA735.09NANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Property Plant And Equipment Net 33.8933.4233.4832.4528.8223.8114.8510.818.738.268.769.3310.0110.3611.0311.1111.7612.5111.8111.23NA
Other Assets Noncurrent 10.6010.5210.897.737.905.786.186.252.251.320.960.870.260.320.320.280.200.200.201.50NA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Liabilities Current 177.18164.02161.25166.08142.87130.37132.06121.67162.8740.0221.0022.7121.0626.5119.0016.9316.6116.3814.2612.73NA
Accounts Payable Current 10.5521.9818.0910.2613.2216.9624.5415.688.1012.052.434.702.902.452.833.102.115.393.923.82NA
Accrued Income Taxes Current 0.020.022.821.81NANANANANANANANANANANANANANANANANA
Accrued Liabilities Current 20.5314.4416.2024.1814.629.717.549.547.505.6110.179.529.6615.557.636.026.674.343.613.14NA
Other Liabilities Current 2.982.47NA0.050.210.382.383.573.421.461.411.481.491.511.541.561.581.651.730.77NA
Contract With Customer Liability Current 103.2990.1289.31102.0074.3474.5774.5774.57115.617.007.007.007.007.007.00NANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Other Liabilities Noncurrent 16.1714.6813.875.2610.2010.2010.2010.258.180.690.640.811.031.281.541.792.052.312.550.56NA
Operating Lease Liability Noncurrent 119.19121.34114.81116.8948.9449.7414.7115.24NANANANANANANANANANANANANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Stockholders Equity 698.70747.39796.58841.45542.61604.55664.79502.30544.42428.71140.64163.84177.23196.65221.57234.94245.12254.57266.59-72.33NA
Common Stock Value 0.010.010.010.010.010.010.010.010.010.010.000.000.000.000.000.00NANANANANA
Additional Paid In Capital 1183.391164.601144.581118.061097.411081.341065.56830.44820.66706.71373.43369.10365.90362.90359.82357.87355.76354.38352.870.95NA
Retained Earnings Accumulated Deficit -474.90-409.98-343.35-275.35-554.72-476.75-400.78-328.18-276.33-278.15-233.08-205.33-188.73-166.38-138.29-122.83-110.53-99.72-86.19-73.23NA
Accumulated Other Comprehensive Income Loss Net Of Tax -9.80-7.24-4.66-1.26-0.09-0.05-0.000.040.080.140.290.060.050.110.03-0.11-0.11-0.08-0.10-0.04NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 16.2615.6816.54NA14.5913.3712.76NA6.004.473.46NA2.742.131.67NA1.051.120.66NANA

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Net Cash Provided By Used In Operating Activities -80.96-65.30654.00-62.10-53.76-74.00-66.32-49.88216.26-23.94-31.28-9.47-27.40-19.75-16.84-7.11-11.77-10.88-13.2515.59-24.23
Net Cash Provided By Used In Investing Activities 23.45-215.20-268.0618.91-88.613.0062.83-0.23-387.12-87.0740.06-12.1030.3626.6714.282.51-83.34-16.12-16.49-42.0712.73
Net Cash Provided By Used In Financing Activities 2.534.3514.9311.671.322.23222.121.68107.52328.870.610.52-0.040.65-0.010.77-0.01-1.12129.43106.600.19

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Net Cash Provided By Used In Operating Activities -80.96-65.30654.00-62.10-53.76-74.00-66.32-49.88216.26-23.94-31.28-9.47-27.40-19.75-16.84-7.11-11.77-10.88-13.2515.59-24.23
Net Income Loss -64.92-66.63-67.99279.37-77.97-75.97-72.59-51.851.82-45.07-27.75-16.60-22.35-28.09-17.67-12.29-10.81-13.53-12.95-13.21-23.12
Profit Loss -64.92-66.63-67.99279.37-77.97-75.97-72.59-51.851.82-45.07-27.75-16.60-22.35-28.09-17.67-12.29-10.81-13.53-12.95-13.21NA
Increase Decrease In Accounts Payable -12.163.968.140.65-1.85-11.297.726.11-3.509.01-2.341.820.47-0.05-0.520.96-2.381.65-0.312.04-0.70
Share Based Compensation 16.2615.6816.5413.8114.5913.3712.767.896.004.473.462.442.742.131.671.051.051.120.660.150.14

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Net Cash Provided By Used In Investing Activities 23.45-215.20-268.0618.91-88.613.0062.83-0.23-387.12-87.0740.06-12.1030.3626.6714.282.51-83.34-16.12-16.49-42.0712.73
Payments To Acquire Property Plant And Equipment 1.321.512.798.517.866.073.641.521.070.260.210.200.550.550.630.261.131.301.050.290.84
Payments To Acquire Investments 322.26385.56377.57134.01214.16178.29192.40170.75429.21130.808.8867.5156.4151.4372.4139.48131.4049.5941.0859.116.28

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Net Cash Provided By Used In Financing Activities 2.534.3514.9311.671.322.23222.121.68107.52328.870.610.52-0.040.65-0.010.77-0.01-1.12129.43106.600.19

    2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30
Revenues 33.5826.7618.00354.509.469.469.469.4964.531.751.759.751.751.751.751.564.291.251.251.250.16
Gilead Sciences Inc And Taiho Pharmaceutical Co, License And Development Services Revenue 23.7416.697.94NANANANANANANANANANANANANANANANANANA
Gilead Sciences Inc And Taiho Pharmaceutical Co, Other Collaboration Revenue 9.8410.0710.079.539.469.469.46NANANANANANANANANANANANANANA
Gilead Sciences Inc And Taiho Pharmaceutical Co, License And Service 33.5826.7618.00354.509.469.469.469.4964.531.751.759.751.75NANANANANANANANA
Revenue From Contract With Customer Excluding Assessed Tax 33.5826.7618.00354.509.469.469.469.4964.531.751.759.751.751.751.751.564.291.251.251.250.16
Gilead Sciences Inc, Option License And Collaboration Agreement 2.3013.205.00NANANANANANANANANANANANANANANANANANA
Gilead Access Rights 8.328.328.327.787.717.717.717.747.68NANANANANANANANANANANANA
License And Development Services For All Gilead Programs 23.7416.697.94NANANANANANANANANANANANANANANANANANA
License And Development Services Revenue 23.7416.697.941.140.000.00NANANANANANANANANANANANANANANA
Other Collaboration Revenue 9.8410.0710.079.539.469.469.46NANANANANANANANANANANANANANA
Taiho Access Rights 1.521.751.751.751.751.751.75NANANANANANANANANANANANANANA
Access Rights Related To Research And Development Pipeline 8.308.308.307.807.707.707.70NANANANANANANANANANANANANANA
Option License And Collaboration Agreement 8.90NANANANANANANANANANANANANANANANANANANANA
Quemliclustat Options License And Research And Development Activities Agreement 12.701.901.80NANANANANANANANANANANANANANANANANANA
Research And Development Activities For Domvanalimab 0.201.300.90NANANANANANANANANANANANANANANANANANA
Research And Development And Commercialization Activities For Zimberelimab Monotherapy 8.500.300.30NANANANANANANANANANANANANANANANANANA

Plots across concepts


IncomeStatement
Operating Income Loss
Expenses
Income Tax Expense Benefit
Balance Sheet
Operating Lease Right Of Use Asset
Assets
Property Plant And Equipment Net
Current Assets
Prepaid Expense And Other Assets Current
NonCurrent Assets
Other Assets Noncurrent
Liabilities
Liabilities Current
Current Liabilities
Accrued Income Taxes Current
Stockholders Equity
Retained Earnings Accumulated Deficit
CashFlow
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInInvestingActivities
Payments To Acquire Property Plant And Equipment
Shares
Weighted Average Number Of Share Outstanding Basic And Diluted

Line plots across dimensions of each concept


TTM Greenblatt ROC
_
(None,)
T T M  Greenblatt  R O C_
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService
('rcus:GileadSciencesIncAndTaihoPharmaceuticalCo', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service
us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)
Allocated Share Based Compensation Expenseus-gaap: Income Statement Location
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:InvestmentType
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Investment Type
us-gaap:AvailableForSaleSecuritiesDebtSecurities
us-gaap:FinancialInstrument
(None,)
Available For Sale Securities Debt Securitiesus-gaap: Financial Instrument
us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)
Stockholders Equityus-gaap: Statement Equity Components
us-gaap:Revenues
us-gaap:CounterpartyName, us-gaap:ProductOrService
('rcus:GileadSciencesIncAndTaihoPharmaceuticalCo', None)
Revenuesus-gaap: Counterparty Name, us-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Product Or Service
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TypeOfArrangement
(None,)
Revenue From Contract With Customer Excluding Assessed Taxus-gaap: Type Of Arrangement